Search results
Results from the WOW.Com Content Network
The Finger Plan (Danish: Fingerplanen) is an urban plan from 1947 which provides a strategy for the development of the Copenhagen metropolitan area, Denmark. According to the plan, Copenhagen is to develop along five 'fingers', centred on S-train commuter rail lines, which extend from the 'palm', that is the dense urban fabric of central ...
In March 2017, ocrelizumab was approved in the United States for the treatment of primary progressive multiple sclerosis in adults. [22] [42] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. [42]
Christian Erhardt Bredsdorff, commonly known as Peter Bredsdorff, (1913–1981) was a Danish architect and urban planner who is remembered for his Finger Plan for the development of Copenhagen. In this connection, his name is included in the Danish Culture Canon. [1] [2]
The most widely accepted is the area which is strategically managed by the Finger Plan. The modern post 2007 version includes the four provinces Københavns by (Copenhagen city), Københavns omegn , Nordsjælland and Østsjælland , with a total land area of 2 778 km 2 and over 2 million inhabitants (16 March 2018;updated statistics from 1 ...
In 1949, Copenhagen Municipality implemented the Finger Plan: a policy stating that the city should develop urban clusters along its five outreaching rapid public transport arteries. [7] This early example of transit orientated development resonates with Howard’s ideal of developing periphery communities linked with productive urban centres ...
The second trial was a two-year, multi-center, randomized, double-blind, placebo controlled trial and involved 251 patients. [14] The third trial was a double-blind MRI study involving participation of 239 patients. [15] A 15-year followup of the original trial compared patients who continued with glatiramer to patients who dropped out of the ...
[22] [11] When the FDA approved the drug, it required Roche to conduct several Phase IV clinical trials, including: a two-part study in people between ten and 17 years old with relapsing multiple sclerosis to determine dosing, then safety and efficacy in these people, required to be completed by 2024; a prospective five-year study to better ...
The presence of demyelinating white matter lesions on brain MRIs at the time of presentation for optic neuritis is the strongest predictor in developing clinical diagnosis of MS. Almost half of patients with optic neuritis have white matter lesions consistent with multiple sclerosis. At five year follow-ups the overall risk of developing MS is ...